ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional

Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)

ClinicalTrials.gov ID: NCT03495882

Public ClinicalTrials.gov record NCT03495882. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 4:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 / 2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors

Study identification

NCT ID
NCT03495882
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Agenus Inc.
Industry
Enrollment
154 participants

Conditions and interventions

Interventions

  • AGEN1884 + AGEN2034 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 17, 2017
Primary completion
Jul 14, 2022
Completion
Jul 14, 2022
Last update posted
Jul 4, 2023

2017 – 2022

United States locations

U.S. sites
13
U.S. states
11
U.S. cities
13
Facility City State ZIP Site status
Comprehensive Care and Research Center Goodyear Arizona 85338
City of Hope National Medical Center Duarte California 91010
University of Miami Miami Florida 33136
BRCR Medical Center, Inc Plantation Florida 33322
Augusta University Augusta Georgia 30912
Cancer Treatment Centers of America Zion Illinois 60099
Ochsner Cancer Institute New Orleans Louisiana 70121
West Michigan Cancer Center Kalamazoo Michigan 49007
University of Oklahoma Oklahoma City Oklahoma 73104
Chattanooga's Program In Women's Oncology Chattanooga Tennessee 37403
CliniCore International Baytown Texas 77521
Providence Regional Cancer System Aberdeen Washington 98520
Swedish Cancer Institute Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03495882, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 4, 2023 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03495882 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →